GlassScriptPhysician profile
James Henry Pridgen
NPI 1215083563
$1,396.67
in general payments reported to CMS, 2019-2025
23 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2021: $175 · 2022: $113 · 2023: $329 · 2024: $248 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $992.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $348.34 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $246.65 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Biohaven Pharmaceuticals, INC. | $121.26 | 2021 | |
| Abbvie INC. | $115.36 | 2022-2023 | |
| Novo Nordisk INC | $79.32 | 2021-2024 | Rybelsus, Ozempic |
| Azurity Pharmaceuticals, INC. | $68.98 | 2023-2025 | Edarbyclor, Alvesco, Edarbi |
| Amgen INC. | $67.31 | 2022-2025 | Repatha, Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.72 | 2025 | Caplyta |
| Astellas Pharma US INC | $37.67 | 2023-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.98 | 2024 | Jardiance |
| Esperion Therapeutics, INC. | $28.10 | 2023-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $24.73 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $20.55 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $20.34 | 2019 | |
| Phadia US INC. | $20.34 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $17.72 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.33 | 2024 | Xifaxan |
| Genentech USA, INC. | $14.97 | 2021 | |
| Vanda Pharmaceuticals INC. | $14.87 | 2024 | Hetlioz, Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $14.71 | 2024 | Trintellix |
| Viiv Healthcare Company | $13.90 | 2021 | |
| Medtronic, INC. | $13.19 | 2024 | Vanta Adaptivestim |
| Arbor Pharmaceuticals, INC. | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Pridgen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.